Vitravene Articles
Isis on a roll as it signs another licence deal
12 December 2012
Novartis withdraws Vitravene MA in EU
12 August 2002
Swiss major Novartis Pharma pulls out of Isis cancer drug deal
23 November 1999
Vitravene OKed in Europe
5 August 1999
Vitravene backed in EU
29 April 1999
Isis, Elan link up for oral antisense drugs
13 April 1999
US biotech drug sales to grow 13% pa to 2002
29 March 1999
Vitravene Debuts On US Market
5 November 1998
US Third-Quarter Results In Brief
4 November 1998
Antisense '98 - The Key Players In R&D
22 October 1998
Isis Gets $7.5 Million Milestone
22 September 1998
FDA Approves Isis And CIBA Vision's Vitravene
1 September 1998
FDA Panel Recommends Fomivirsen Be Approved
23 July 1998
Vitravene NDA accepted
2 July 1998
Isis And Ciba File MAA For Fomivirsen
7 May 1998
Latest Wave Of US 1st Quarter Results
7 May 1998
Isis Files First Antisense NDA
15 April 1998
Fomivirsen Delays CMV Retinitis Progression
8 April 1998
Fomivirsen Completes Phase III Study
12 February 1998
Clinical Trial News In Brief
20 January 1998
US 3rd Qtr Corporate Results Round-Up
30 October 1997
Ciba To Market Fomivirsen On Approval
17 July 1997
Isis Pharmaceuticals' Phase I Cancer Drugs
12 May 1997
"Control" Of CMV Retinitis With Isis Drug
24 February 1997
Isis Receives $10m From BI For ISIS 2302
16 December 1996
Isis Pharmaceuticals Revise Fomivirsen Agreement With Eisai
19 August 1996
Isis' CMV Antisense Effective And Safe
29 April 1996
Showing 1-33 of 33 articles
- 1
- Aspen Pharma offers to buy GlaxoSmithKline's thrombosis brands and manufacturing site
- US Supreme Court says patent settlement can "sometimes" be illegal
- Athera and Boehringer Ingelheim enter option agreement on a novel therapy for atherosclerosis
- FDA probes two deaths possibly linked to Lilly's antipsychotic Zyprexa Relprevv
- Australia's pharma industry applauds R&D regulatory reform
